NR1I3 and Ito hypomelanosis: Host genetic polymorphisms (e.g., pregnane X receptor (PXR)/constitutive androstane receptor (CAR) variants) may modulate the efficacy of IPA; however, this aspect has not been thoroughly investigated [69].